Hindustan Bio Sciences Limited has successfully completed the newspaper publication of its unaudited financial results for Q3FY26, demonstrating compliance with regulatory requirements following its strong quarterly performance. The Hyderabad-based pharmaceutical company reported a profit of ₹8.20 lakhs for the quarter ended December 31, 2025, marking a significant turnaround from previous quarters.

Regulatory Compliance and Publication

The company has fulfilled its obligation under Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, by publishing its Q3FY26 unaudited financial results in newspapers. Managing Director Venkata Rama Mohan Raju Jampana (DIN: 00060800) confirmed the publication details in a formal intimation to BSE Limited on February 2, 2026.

Financial Performance Highlights

The company's Q3FY26 performance demonstrates remarkable improvement with total income reaching ₹40.03 lakhs, comprising revenue from operations of ₹1.78 lakhs and other income of ₹38.25 lakhs. This represents a substantial increase from the previous quarter where total income was only ₹0.86 lakhs.

Nine-Month Performance Overview

For the nine-month period ended December 31, 2025, Hindustan Bio Sciences reported positive results with a profit of ₹3.74 lakhs compared to a loss of ₹0.98 lakhs in the corresponding period of the previous year. Total income for the nine-month period reached ₹74.39 lakhs against ₹42.20 lakhs in the previous year, representing a growth of 76.30%.

Board Meeting and Compliance

The Board Meeting was held on January 31, 2026, at 2:00 PM at the company's registered office located at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad. The meeting concluded at 3:30 PM, during which directors approved the unaudited financial results along with the Limited Review Report. The results were subject to limited review by VASG & Associates, Chartered Accountants (FRN: 006070S).

Company Information

Hindustan Bio Sciences Limited operates from its registered office at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad-500034. The company maintains its corporate identity number as L26942TG1991PLC013564 and can be contacted at +91 40 23555161/23555181. The paid-up equity capital remains constant at ₹205.02 lakhs with a face value of ₹2.00 per share.

Source: Company Filing

Hindustan bio sciences Limited has filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reporting the acquisition of shares by Bosco Armando Menezes and Emily Bosco Menezes on January 23, 2026.

Share Acquisition Details

The acquisition involved the purchase of 15,000 shares through open market transactions on January 22, 2026. The acquirers, Bosco Armando Menezes and Emily Bosco Menezes, are not part of the promoter group of the company.

Shareholding Pattern Changes

Prior to this acquisition, the combined holding of both acquirers stood at 5,10,000 shares, representing 4.98% of the total voting capital. The recent purchase has increased their combined shareholding to 5,25,000 shares, representing 5.12% of the company's total voting capital.

Individual Shareholding Breakdown

The disclosure reveals the individual shareholding pattern of both acquirers. Bosco Armando Menezes and Emily Bosco Menezes each held 2,55,000 shares before the acquisition. After the purchase, their combined voting rights increased to 2,70,000 shares, while maintaining 2,55,000 shares in encumbered form.

Company Capital Structure

The company's equity share capital remains unchanged following this transaction. Hindustan Bio Sciences Limited maintains its equity share capital at Rs.2,05,01,600, consisting of 1,02,50,800 equity shares of Rs.2 each. The company's shares are listed on BSE Limited.

The disclosure was signed by J V R Mohan Raju, Managing Director of Hindustan Bio Sciences Limited, and filed with BSE Limited on January 23, 2026, in compliance with SEBI regulations for substantial acquisition of shares.